Celgene Thalomid Multiple Myeloma sNDA Is "Approvable"

Celgene said that it will submit a completed study which compares thalidomide plus dexamethasone to dexamethasone alone in previously untreated patients, as well as additional data. Accelerated approval is possible in six to nine months, the company says.